Encapsulated cells releasing NGF to the basal forebrain in ten AD patients with ongoing treatment with ChEIs resulted in increased levels of ChAT activity in CSF (Karami et al., 2015; Eyjolfsdottir et al., 2016). This evidence concerns the gene NGF and Alzheimer disease.